Community Acquired Infections, Gram-positive Bacterial Infections, Pneumonia, Pneumococcal
Conditions
Keywords
Pharmacia
Brief summary
This study will treat patients who have a community-acquired pneumonia that is due to a specific bacteria (S. pneumoniae)
Interventions
DRUGAntibiotic
Sponsors
Pfizer
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
13 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Other specific inclusion/
Exclusion criteria
may apply. In order to determine eligibility, further examination by the investigator is necessary. Inclusion Criteria: * Patients must have the signs and symptoms of pneumonia, with a chest xray showing a pneumonia. * The patient must have S. pneumoniae (a specific bacteria) growing in sputum or blood to continue treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the microbiologic efficacy of linezolid in the treatment of patients with pneumonia caused by penicillin-resistant Streptococcus pneumoniae (PRSP). | — |
| Additionally, microbiologic efficacy will be assessed in all pneumonia patients infected with S pneumoniae SP) and in those infected with penicillin-sensitive (PSSP) and penicillin-intermediate (PISP) S pneumoniae. | — |
Secondary
| Measure | Time frame |
|---|---|
| To assess clinical efficacy and safety in pneumonia patients infected with S pneumoniae. | — |
Countries
Slovakia, Spain, Taiwan, United States
Outcome results
None listed